摘要
狼疮性肾炎(LN)在我国发病率相对较高,患者个体差异大,同时各医疗中心的治疗选择不尽相同,不利于LN患者的规范化治疗。2011年,国际改善全球肾脏病预后组织(KDIGO)颁布的肾小球肾炎临床诊疗指南,对LN的治疗在组织病理分型基础上做了详细的阐述。本文以KDIGO指南为基础,结合临床实际以及其他组织新发布的指南,就中国LN患者的一般治疗及免疫抑制治疗提出新的解读。
Summary：The 2011 Kidney Disease： Improving Global Outcome （KDIGO） guideline has delineated the treatment of lupus nephrits （LN） based on pathological classification of glomerulonephritis. The comparatively high prevelence of LN, varying between-individual difference and various treatment protocols among institutions in China may have hampered standarization of therapy. On the basis of KDIGO guideline,the present review targeted at interpreting general treatment protocols and ad- ministration of immunosuppressants in Chinese patients with LN by means of integrating with routine clinical practice and latest guidelines released by miscellaneous organizations.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2012年第12期921-924,共4页
Chinese Journal of Practical Internal Medicine
